Matthews Asia Innovators Active ETF MINV 深 沪
等待开盘 11-03 09:30:00 美东时间
37.4196
-0.023
-0.06%
华盛通- 最 高37.45
- 今 开37.35
- 成交量 1083股
- 最 低 37.30
- 昨 收 37.4422
- 总市值 7671.02万
- 52周最高 38.559
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 24.18
- 委 比 0.00%
- 总股本 205.00万
- 历史最高 38.559
- 量 比 0.17
- 振 幅 0.40%
- 历史最低 19.1583
- 每 手 1
- 风险率 3.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences, Inc. has raised up to $200 million to advance the Phase 3 trial of roluperidone for treating negative symptoms of schizophrenia. The proceeds, including $80 million upfront and additional $80 million via Tranche A warrants, will fund the confirmatory trial and NDA resubmission. Up to $40 million more could be received from Tranche B warrants upon milestone achievements. Three new directors with schizophrenia trial experienc...
10-21 12:00
Knight Therapeutics Expands Incyte Partnership To Distribute ZYNYZ And NIKTIMVO In Latin America
Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences
08-05 04:41
Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth
Minovia Therapeutics reports positive interim results from its Phase 2 trial of MNV-201 for Pearson Syndrome, showing a favorable safety profile and early signs of efficacy in three patients. Two compassionate use patients with Kearns-Sayre syndrome also demonstrated improved quality of life. The FDA has granted Fast Track and Rare Pediatric Disease Designations to MNV-201. Minovia plans to finalize enrollment in the trial and advance toward pivo...
07-24 12:15
